News
10-17-2010, 03:04 AM
The National Institute for Health and Clinical Excellence (NICE) has published the outcome of an appeal hearing relating to its draft guidance on the use of lapatinib (Tyverb, GlaxoSmithKline) for certain breast cancer patients...
More... (http://mnt.to/f/3Ljx)
More... (http://mnt.to/f/3Ljx)